Evaluation of Maternal Serum Placental Protein 13 and Soluble Endoglin as Predictive Biomarkers for Preeclampsia
Medical Science Journal for Advance Research · 19.07.2026 · 7 (2)
DOI: 10.46966/msjar.v7i2.423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Science Journal for Advance Research, online erschienen am 19.07.2026. Verfasst von Saba Muhammed Jassim. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Preeclampsia involves placental dysfunction and maternal endothelial injury that may be reflected by altered placental protein 13 (PP13) and soluble endoglin (sEng).
Objective
To evaluate serum PP13 and sEng, individually and jointly, for distinguishing established preeclampsia from healthy pregnancy. Materials and methods: This hospital-based case-control study included 50 women with preeclampsia and 50 healthy pregnant controls; 27 cases were coded mild and 23 severe. Groups were compared using Welch’s t, Mann–Whitney U, or Kruskal–Wallis tests with Holm-adjusted pairwise comparisons. ROC curves quantified discrimination, and repeated five-fold cross-validation assessed internal model performance.
Results
PP13 was lower in preeclampsia than controls (84.28 ± 17.97 versus 154.24 ± 25.76; P
Zitieren
APA
Jassim, S. M. (2026). Evaluation of Maternal Serum Placental Protein 13 and Soluble Endoglin as Predictive Biomarkers for Preeclampsia. Medical Science Journal for Advance Research, 7(2). https://doi.org/10.46966/msjar.v7i2.423
Vancouver
Jassim SM. Evaluation of Maternal Serum Placental Protein 13 and Soluble Endoglin as Predictive Biomarkers for Preeclampsia. Medical Science Journal for Advance Research. 2026;7(2). doi:10.46966/msjar.v7i2.423
BibTeX
@article{Jassim2026,
author = {Jassim, Saba Muhammed},
title = {Evaluation of Maternal Serum Placental Protein 13 and Soluble Endoglin as Predictive Biomarkers for Preeclampsia},
journal = {Medical Science Journal for Advance Research},
year = {2026},
volume = {7},
number = {2},
doi = {10.46966/msjar.v7i2.423}
}
EUVIMED